Rezolute, Inc. has a 260% upside potential with positive feedback on Phase 3 trials.

From Yahoo Finance: 2025-05-20 12:08:00

Rezolute, Inc. (NASDAQ:RZLT) has a 260% upside potential over the next 12 months, making it one of the 13 Best Multibagger Stocks to Invest in Now. The company focuses on rare diseases, with its lead candidate, ersodetug, targeting congenital hyperinsulinism. Rezolute recently received positive feedback to continue Phase 3 trials.

Rezolute, Inc. is a late-stage biopharmaceutical company founded in 2010. Its main product candidate, ersodetug, is in Phase 3 trials for congenital hyperinsulinism, while RZ402 is undergoing Phase 2 testing for diabetic macular edema. The company’s unique approach and regulatory advantages set it apart in the industry.

With $120 million in financing secured, Rezolute is well-positioned for the development of ersodetug. Analysts have a buy rating on the stock, with a consensus price target of $13.44, indicating a 260.32% upside potential. Despite its promise, some believe other AI stocks may offer greater returns with limited downside risk.



Read more at Yahoo Finance: Analysts See 260% Upside Potential